Vimarsana
Biggest News Aggregation in the World

Page 42 - Nuclear Export News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nuclear Export. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nuclear Export Today - Breaking & Trending Today

Karyopharm Announces New Interim Phase 2 Selinexor Data in Myelofibrosis Selected for Oral Presentation at the American Society of Hematology 2021 Annual Meeting and Exposition - Vimarsana News

Karyopharm Announces New Interim Phase 2 Selinexor Data in Myelofibrosis Selected for Oral Presentation at the American Society of Hematology 2021 Annual Meeting and Exposition

Published: November 4, 2021

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Source: prnewswire.com
Related Topics:
United StatesEltanexor MonotherapyPraneeth SudalaguntaSuresh Kumar BalasubramanianH Lee MoffittYuki NishidaMarie MaerevoetSrinivas TantravahiDarrell WhiteSuzanne LentzschWaldenstrom MacroglobulinemiaJatin ShahSangmin LeePiroska KlementPaula RodrSundar JagannathPaula RestrepoMuhamed BaljevicYael CohenNizar BahlisSelective Inhibitor Of Nuclear ExportColumbia University Irving Medical CenterCompany To Host Investor Day EventMount Sinai School Of MedicineJules Bordet Institute
Karyopharm Announces New Interim Phase 2 Selinexor Data in Myelofibrosis Selected for Oral Presentation at the American Society of Hematology 2021 Annual Meeting and Exposition - Vimarsana News

Karyopharm Announces New Interim Phase 2 Selinexor Data in Myelofibrosis Selected for Oral Presentation at the American Society of Hematology 2021 Annual Meeting and Exposition

Published: November 4, 2021

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Source: prnewswire.com
Related Topics:
United StatesEltanexor MonotherapyPraneeth SudalaguntaSuresh Kumar BalasubramanianH Lee MoffittYuki NishidaMarie MaerevoetSrinivas TantravahiDarrell WhiteSuzanne LentzschWaldenstrom MacroglobulinemiaJatin ShahSangmin LeePiroska KlementPaula RodrSundar JagannathPaula RestrepoMuhamed BaljevicYael CohenNizar BahlisSelective Inhibitor Of Nuclear ExportColumbia University Irving Medical CenterCompany To Host Investor Day EventMount Sinai School Of MedicineJules Bordet Institute
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Vimarsana News

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Published: November 1, 2021

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Source: prnewswire.com
Related Topics:
Karyopharm Therapeutics IncKaryopharm Selective Inhibitor Of Nuclear ExportCompensation Committee Of Karyopharm Board DirectorsEuropean CommissionKaryopharm TherapeuticsCompensation CommitteeNasdaq Listing RuleSelective InhibitorNuclear ExportKaryopharm Therapeutics IncPharmaceuticals Health Care Amp Hospitals Medical Pharmaceuticals
Karyopharm to Report Third Quarter 2021 Financial Results on November 3, 2021 - Vimarsana News

Karyopharm to Report Third Quarter 2021 Financial Results on November 3, 2021

Published: October 27, 2021

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Source: prnewswire.com
Related Topics:
Prnewswire Karyopharm Therapeutics IncKaryopharm Therapeutics IncKaryopharm Selective Inhibitor Of Nuclear ExportEuropean CommissionKaryopharm TherapeuticsSelective InhibitorNuclear ExportKaryopharm Therapeutics Inc
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Vimarsana News

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Published: October 1, 2021

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Source: prnewswire.com
Related Topics:
Karyopharm Therapeutics IncKaryopharm Selective Inhibitor Of Nuclear ExportCompensation Committee Of Karyopharm Board DirectorsEuropean CommissionKaryopharm TherapeuticsCompensation CommitteeNasdaq Listing RuleSelective InhibitorNuclear ExportKaryopharm Therapeutics Inc